"Vertex Pharmaceuticals' $4.9B Acquisition of Alpine Expands Focus to Kidney and Autoimmune Diseases"
TL;DR Summary
Vertex Pharmaceuticals has announced a $4.9 billion deal to acquire Alpine Immune Sciences and its experimental drug povetacicept, aimed at treating IgA nephropathy, a kidney disease. The acquisition will expand Vertex's work in kidney and autoimmune diseases, marking a significant investment from the biotech company.
Topics:business#acquisition#alpine-immune-sciences#autoimmune-disease#business-healthcare#kidney-disease#vertex
- Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease Endpoints News
- Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion CNBC
- Vertex to Buy Kidney Disease Drug Developer for $4.9 Billion Bloomberg
- Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition MarketWatch
- Why Janux Therapeutics Stock Soared as the Market Sagged Today The Motley Fool
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
59%
111 → 45 words
Want the full story? Read the original article
Read on Endpoints News